Skip to content

Time to resumption of spontaneous respiration in patients administered either suxamethonium or rocuronium followed by sugammadex - SUX/SUGAM

Time to resumption of spontaneous respiration in patients administered either suxamethonium or rocuronium followed by sugammadex - SUX/SUGAM

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
EU CTR
Registry ID
EUCTR2009-010840-33-GB
Enrollment
Unknown
Registered
2009-04-16
Start date
2009-08-17
Completion date
Unknown
Last updated
2012-03-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Assessment of time to return of spontaneous ventilation after administration of either suxamethonium or rocuronium followed by sugammadex in patients undergoing planned surgery.

Interventions

Trade Name: BRIDION Product Name: SUGAMMADEX Pharmaceutical Form: Solution for injection Other descriptive name: SUGAMMADEX Concentration unit: mg/ml milligram(s)/millilitre Concentration type: equal

Sponsors

BELFAST HEALTH & SOCIAL CARE TRUST
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: i) ASA class I-III ii) Patients able to give written informed consent iii) Patients requiring general anaesthesia iv) Patients aged 18 – 65 Are the trial subjects under 18? no Number of subjects for this age range: F.1.2 Adults (18-64 years) yes F.1.2.1 Number of subjects for this age range F.1.3 Elderly (>=65 years) no F.1.3.1 Number of subjects for this age range

Exclusion criteria

Exclusion criteria: i) History of dementia or difficulty in providing informed consent ii) Patients with chronic obstructive pulmonary disease (COPD) iii) Patients with a history of ischaemic heart disease (IHD) iv) Patients with a haemoglobin concentration of less than 10g dl-1 v) Patients with a history of known difficulty in intubation or with an anticipated challenging airway vi) Pregnancy vii) Patients with a history of allergy to any of the medications used in the study

Design outcomes

Primary

MeasureTime frame
Main Objective: Length of time to resumption of spontaneous ventilation as indicated by visible diaphragmatic movement or decrease in oxygen saturation to = 90% before onset of spontaneous ventilation;Secondary Objective: (i) Frequency of desaturation to = 90% (ii) Length of time to movement of reservoir bag (iii) Length of time to first capnographic evidence of ventilation (iv) Incidence of adverse events in all groups ;Primary end point(s): The primary end point is the time to resumption of spontaneous ventilation after administration of suxamethonium or rocuronium followed by sugammadex.

Countries

United Kingdom

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026